{"id":"atropine-sulfate-eye-drops-0-01","safety":{"commonSideEffects":[{"rate":null,"effect":"Mydriasis (pupil dilation)"},{"rate":null,"effect":"Cycloplegia (accommodation paralysis)"},{"rate":null,"effect":"Photophobia (light sensitivity)"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular irritation or redness"}]},"_chembl":{"chemblId":"CHEMBL1396281","moleculeType":"Small molecule","molecularWeight":"387.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine competitively blocks muscarinic receptors on the ciliary muscle and iris sphincter muscle, preventing acetylcholine-induced contraction. This results in cycloplegia (paralysis of accommodation) and mydriasis (pupil dilation). At the low 0.01% concentration, atropine is used primarily for myopia control by reducing accommodation-driven axial elongation in the eye.","oneSentence":"Atropine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic signaling in the eye to inhibit accommodation and pupil constriction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:58.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myopia control in children"},{"name":"Cycloplegia for refraction"}]},"trialDetails":[{"nctId":"NCT07494799","phase":"","title":"Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-04-01","conditions":"Progressive Myopia, Pediatric Myopia, Orthokeratology-related Myopia Progression","enrollment":3890},{"nctId":"NCT07475585","phase":"NA","title":"Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve","status":"NOT_YET_RECRUITING","sponsor":"Fangbiao Tao","startDate":"2026-03-30","conditions":"Myopia, Ear Acupressure Pellets, Hyperopia Reserve","enrollment":380},{"nctId":"NCT07456488","phase":"PHASE2","title":"The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group","status":"RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07-13","conditions":"Focus on Axial Length","enrollment":60},{"nctId":"NCT07449247","phase":"PHASE1, PHASE2","title":"PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-03-30","conditions":"Pre-myopia","enrollment":233},{"nctId":"NCT04923841","phase":"NA","title":"Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2021-09-09","conditions":"Myopia","enrollment":579},{"nctId":"NCT07406399","phase":"PHASE4","title":"Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2023-06-30","conditions":"High Myopia, Low Concentration Atropine, Soft Contact Lens","enrollment":120},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT07176949","phase":"NA","title":"Early-Onset Myopia Intervention Project","status":"RECRUITING","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2025-06-01","conditions":"Myopia, Pre-myopia","enrollment":508},{"nctId":"NCT07129889","phase":"NA","title":"Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Eye Hospital","startDate":"2025-12-02","conditions":"Myopia","enrollment":180},{"nctId":"NCT07120165","phase":"","title":"Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-20","conditions":"Myopia","enrollment":114},{"nctId":"NCT03911271","phase":"PHASE2","title":"Low-dose Atropine for the Prevention of Myopia Progression in Danish Children","status":"COMPLETED","sponsor":"Line Kessel","startDate":"2019-05-30","conditions":"Myopia","enrollment":97},{"nctId":"NCT06200194","phase":"PHASE2","title":"Early Intervention for Premyopic Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Yang Ming Chiao Tung University Hospital","startDate":"2024-10-06","conditions":"Myopia, Preschool","enrollment":240},{"nctId":"NCT06389110","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-03-15","conditions":"Myopia, Myopia, Progressive","enrollment":123},{"nctId":"NCT04252989","phase":"","title":"Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2019-12-18","conditions":"Myopia, Children","enrollment":50},{"nctId":"NCT03865160","phase":"PHASE2, PHASE3","title":"Low-dose Atropine for Myopia Control in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Eye Hospital, Freiburg","startDate":"2021-10-19","conditions":"Myopia, Progressive","enrollment":302},{"nctId":"NCT05379855","phase":"NA","title":"A-eyedrops on Ocular Alignment and Binocular Vision","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-03-02","conditions":"Exotropia, Exophoria, Myopia","enrollment":339},{"nctId":"NCT03942419","phase":"PHASE3","title":"Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression","status":"TERMINATED","sponsor":"Eyenovia Inc.","startDate":"2019-06-03","conditions":"Myopia","enrollment":438},{"nctId":"NCT06708156","phase":"PHASE3","title":"The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression","status":"RECRUITING","sponsor":"Oupushifang Pharmaceutical Technology Co., Ltd.","startDate":"2024-06-15","conditions":"Myopia, Myopia Progression","enrollment":606},{"nctId":"NCT06727019","phase":"NA","title":"Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2023-04-10","conditions":"Myopia","enrollment":138},{"nctId":"NCT06697522","phase":"PHASE3","title":"Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children","status":"COMPLETED","sponsor":"Ocumension Therapeutics (Suzhou) Co., Ltd","startDate":"2023-06-25","conditions":"Myopia","enrollment":148},{"nctId":"NCT03374306","phase":"NA","title":"Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate","status":"COMPLETED","sponsor":"The Hong Kong Polytechnic University","startDate":"2018-02-01","conditions":"Myopia","enrollment":71},{"nctId":"NCT04173780","phase":"PHASE2, PHASE3","title":"Topical 0.01% Atropine for the Control of Fast Progressing Myopia","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-02-12","conditions":"Myopia Progressing, Childhood","enrollment":60},{"nctId":"NCT06029530","phase":"PHASE1","title":"Delaying the Onset of Nearsightedness Until Treatment Study","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2024-01-01","conditions":"Myopia","enrollment":""},{"nctId":"NCT06265454","phase":"PHASE2","title":"Low Dose Atropine Eye Drops in Myopic Egyptian Children","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-09-01","conditions":"Myopia Progression, Axial Length, Eye, Sclera Thickness","enrollment":75},{"nctId":"NCT06174935","phase":"PHASE2","title":"Low Dose Atropine for Symptomatic Vitreous Floaters","status":"UNKNOWN","sponsor":"Jeanette Du","startDate":"2024-01-01","conditions":"Vitreous Floaters","enrollment":200},{"nctId":"NCT06034366","phase":"NA","title":"the Efficacy of 0.01% Atropine for Near Work-induced Transient Myopia and Myopic Progression","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-10-01","conditions":"Myopia","enrollment":150},{"nctId":"NCT06071260","phase":"NA","title":"Effect of Atropine on Pupil Size and Quality of Vision","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-12-01","conditions":"Myopia, Progressive","enrollment":40},{"nctId":"NCT03690089","phase":"PHASE2","title":"Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom","status":"ACTIVE_NOT_RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-04-03","conditions":"Myopia","enrollment":289},{"nctId":"NCT03334253","phase":"PHASE3","title":"Low-Dose Atropine for Treatment of Myopia","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2018-06-01","conditions":"Myopia","enrollment":200},{"nctId":"NCT04770610","phase":"PHASE3","title":"Study of OT-101 in Treating Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocumension (Hong Kong) Limited","startDate":"2021-04-01","conditions":"Myopia, Progressive","enrollment":678},{"nctId":"NCT05939882","phase":"NA","title":"Low Concentration Atropine in the Prevention of Myopia in Children.","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2023-04-01","conditions":"Myopia, Progressive","enrollment":428},{"nctId":"NCT04290039","phase":"PHASE1","title":"Sublingual vs IV Atropine Bioavailability Study","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2020-01-04","conditions":"Toxic Effect of Organophosphate and Carbamate Insecticides","enrollment":15},{"nctId":"NCT05683535","phase":"","title":"Adverse Events Related to Low Dose Atropine","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2018-06-19","conditions":"Myopia, Progressive","enrollment":148},{"nctId":"NCT05803863","phase":"PHASE4","title":"Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2023-04-15","conditions":"Myopia","enrollment":108},{"nctId":"NCT05597163","phase":"NA","title":"Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2023-01-15","conditions":"Myopia, Progressive","enrollment":588},{"nctId":"NCT03593044","phase":"PHASE1, PHASE2","title":"Side Effects of Atropine (SEA) Study","status":"COMPLETED","sponsor":"Jeffrey J. Walline, OD PhD","startDate":"2018-07-23","conditions":"Myopia","enrollment":31},{"nctId":"NCT05357326","phase":"PHASE4","title":"Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2021-07-01","conditions":"Myopia","enrollment":186},{"nctId":"NCT05090592","phase":"","title":"Influence of Corneal Biomechanical Properties on Myopia Control","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2021-01-01","conditions":"Myopia","enrollment":100},{"nctId":"NCT02955927","phase":"NA","title":"Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial","status":"COMPLETED","sponsor":"The Hong Kong Polytechnic University","startDate":"2016-11","conditions":"Myopia","enrollment":89},{"nctId":"NCT02870478","phase":"PHASE3","title":"The Effects of Low Concentration Atropine on Pupil Size and Accommodation","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2016-07","conditions":"Myopia","enrollment":32},{"nctId":"NCT03508817","phase":"EARLY_PHASE1","title":"Atropine 0.01% Eye Drops in Myopia Study","status":"UNKNOWN","sponsor":"Sultan Qaboos University","startDate":"2018-12-20","conditions":"Myopia, Progressive","enrollment":150},{"nctId":"NCT04338373","phase":"PHASE3","title":"Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children","status":"UNKNOWN","sponsor":"The V.P. Vyhodcev Eye Hospital","startDate":"2020-02-17","conditions":"Myopia","enrollment":70},{"nctId":"NCT03949101","phase":"PHASE4","title":"Atropine for Children and Adolescent Myopia Progression Study","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2019-05-08","conditions":"Myopia","enrollment":222},{"nctId":"NCT03544827","phase":"PHASE4","title":"The Effects of Low Dose Atropine on Choroidal Thickness","status":"COMPLETED","sponsor":"State University of New York College of Optometry","startDate":"2018-05-21","conditions":"Myopia","enrollment":36},{"nctId":"NCT03699423","phase":"PHASE1","title":"Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude","status":"COMPLETED","sponsor":"Hai Yen Eye Care","startDate":"2018-03-08","conditions":"Myopia","enrollment":58},{"nctId":"NCT02130167","phase":"NA","title":"Low Concentration Atropine for Myopia Progression in School Children","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2012-08","conditions":"Myopia Progression","enrollment":60},{"nctId":"NCT03402100","phase":"NA","title":"Eye Drops Study for Myopia Control in Schoolchildren","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2014-10-20","conditions":"Myopia, Progressive, Atropine Allergy","enrollment":150},{"nctId":"NCT00371124","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children","status":"UNKNOWN","sponsor":"Singapore National Eye Centre","startDate":"2006-03","conditions":"Myopia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":236,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atropine sulfate eye drops 0.01%","genericName":"Atropine sulfate eye drops 0.01%","companyName":"Oupushifang Pharmaceutical Technology Co., Ltd.","companyId":"oupushifang-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic signaling in the eye to inhibit accommodation and pupil constriction. Used for Myopia control in children, Cycloplegia for refraction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}